User Fee Goals Needed To Balance FDA Caution, Former Counsel Troy Says
Executive Summary
The prescription drug user fee program must be preserved to prevent FDA from becoming overly cautious on drug approvals, former FDA Chief Counsel Dan Troy told the Milken Institute Global Conference in Los Angeles April 18
You may also be interested in...
Drug Safety Debate Will Have Long-Term Effect On New Approvals, Troy Says
The current debate over drug safety will have a visible impact on new drug approvals in up to three years, former FDA Chief Counsel Dan Troy said
Drug Safety Debate Will Have Long-Term Effect On New Approvals, Troy Says
The current debate over drug safety will have a visible impact on new drug approvals in up to three years, former FDA Chief Counsel Dan Troy said
FDA’s Crawford Open To Discussing Independent Drug Safety Office
FDA Acting Commissioner Lester Crawford is willing to consider making the Office of Drug Safety formally independent from drug review activities if he is confirmed as the agency's permanent leader